Welcome to Coulter Partners Global (English)

25 May 2023

Coulter Partners places Chief Development Officer at TargED Biopharmaceuticals

Coulter Partners is pleased to announce the placement of Gerben van 't Klooster as Chief Development Officer (CDO) of TargED Biopharmaceuticals.

TargED is a biotechnology company dedicated to the development of innovative therapies for rare diseases that develops first-in-class biological drugs to improve the treatment of thrombosis.

Gerben van 't Klooster, Ph.D. is a seasoned pharmaceutical executive with over 30 years of experience in drug development and commercialization. He joins TargED from Galapagos, where he most recently served as Senior Vice President, Alliance Management after heading Galapagos’ early development portfolio for many years. Gerben held multiple senior positions in international pharmaceutical and biotech companies Kiadis, Tibotec and Janssen Pharmaceuticals. As CDO, Gerben will be responsible for leading the company's development strategy and ensuring the successful execution of all development programs.

"I am thrilled to be joining TargED at such an exciting time in the company's growth," said Gerben van 't Klooster. "I am looking forward to working with the team to advance the development of our pipeline of innovative therapies and bring hope to patients with rare diseases."

Kristof Vercruysse, CEO of TargED Biopharmaceuticals, expressed his delight at Gerben’s appointment, and looks forward to his contributions. "We are thrilled to welcome Gerben to our team at TargED Biopharmaceuticals. He brings a wealth of experience and expertise that will be invaluable to our efforts to develop our innovative therapy for patients suffering from Thrombosis." said Vercruysse. He added: “This critical hire to TargED was possible thanks to the team at Coulter Partners and their expert knowledge and understanding.

About TargED Biopharmaceuticals
TargED Biopharmaceuticals B.V. is a biotechnology company and spin-off of the University Medical Center Utrecht, that develops first-in-class biological drugs to improve treatment of thrombosis. TargED stands for Targeted Enzyme Delivery. Their biological drugs are unique by using small antibodies (“VhH”) to deliver enzymes to sites of thrombosis, enabling ‘targeted’ thrombolysis. The lead compound is Microlyse, which is currently under development for thrombotic thrombocytopenic purpura (TTP) and Acute Ischemic Stroke (AIS). The objective is to accelerate thrombolysis in all forms of thrombosis, irrespective of the thrombus composition.

For more information, please visit www.targedbiopharmaceuticals.com.


A new version of Coulter Partners is available.